| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SCPB targets adenylate cyclase in cardiac and gill tissues. It stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues, with EC50 values of 0.1 μM and 1.0 μM, respectively. The peptide's cardiac stimulant effects are mediated through this adenylate cyclase activation, leading to increased cyclic AMP levels and subsequent modulation of muscle contractility.
|
|---|---|
| ln Vitro |
In Aplysia, a naturally occurring neuroactive peptide is called small cardioactive peptide B (SCPB). In Aplysia, cardiac stimulant effects of small cardioactive peptide B (SCPB) are observed. The stimulatory impact of small cardioactive peptide B (SCPB), both synthetic and natural, on isolated hearts has been found to have a threshold concentration of 0.01 nM. The physiology of isolated heart and gill preparations from Aplysia californica was examined in relation to the effects of small cardioactive peptide B (SCPB). Furthermore, the effects of FMRFamide (Phe-Met-Arg-Phe-NH2) and short cardioactive peptide B (SCPB) on adenylyl cyclase activity in the granular fractions of heart and gill tissues were studied. It was discovered that when small cardioactive peptide B (SCPB) was perfused via an isolated heart, it caused dose-dependent, reversible alterations in cardiac activity. The lowest concentrations that typically have an impact on changes in heart rate and contractility are 0.001 and 1 pM, respectively. The EC50 values that influence changes in heart rate and contractility are 0.03 and 0.3 nM, respectively. Small cardioactive peptide B (SCPB), with a threshold concentration of 0.01 pM and an EC50 value of 0.03 nM, reduces the amplitude of the gill withdrawal reaction when perfused through isolated gills. The research discovered that at concentrations as high as 1 nM, small cardioactive peptide B (SCPB) reversibly and dose-dependently inhibited the amplitude of the gill withdrawal reaction. Higher amounts typically result in irreversible inhibition. With an EC50 of 0.1 and 1.0 μM, respectively, small cardioactive peptide B (SCPB) increases adenylyl cyclase activity in the granular fraction of heart and gill tissue [1].
SCPB stimulates adenylate cyclase activity in a concentration-dependent manner in particulate fractions of heart and gill tissues. The peptide exhibits EC50 values of 0.1 μM for heart tissue and 1.0 μM for gill tissue. Its activity is tissue-specific, with significantly higher potency in cardiac compared to gill preparations, reflecting its primary role as a cardioregulatory neuropeptide. |
| ln Vivo |
SCPB exerts cardiac stimulant effects in vivo in molluscan model organisms, modulating heart rate and contractility. The peptide's ability to regulate cardiac and neuromuscular functions has been demonstrated in various invertebrate preparations. Specific mammalian in vivo data are not available as SCPB is primarily a tool for invertebrate neurobiology research.
|
| Enzyme Assay |
SCPB's stimulation of adenylate cyclase can be assessed using in vitro enzyme activity assays with particulate fractions from heart or gill tissues. Tissue homogenates are prepared and membrane fractions are incubated with increasing concentrations of SCPB in the presence of ATP. The amount of cyclic AMP produced is measured using a competitive ELISA or radiometric assay. Dose-response curves are generated to determine EC50 values for adenylate cyclase activation.
|
| Cell Assay |
The cellular activity of SCPB is evaluated in primary cell cultures or tissue preparations from molluscan heart or gill. Cells or tissue explants are treated with increasing concentrations of SCPB, and intracellular cyclic AMP levels are measured using ELISA or radioimmunoassay. Changes in cell contractility or calcium flux can also be monitored to assess the functional consequences of adenylate cyclase activation.
|
| Animal Protocol |
SCPB is typically administered via injection or perfusion in molluscan model organisms such as Aplysia or Lymnaea. Following administration, heart rate, contractile force, and neuromuscular activity are monitored to assess the peptide's cardioregulatory and neuromodulatory effects. Dose-response relationships for physiological effects are established by administering increasing concentrations of the peptide.
|
| ADME/Pharmacokinetics |
SCPB has a molecular formula of C43H69N13O13S and a molecular weight of 1008.2 g/mol. It is a peptide that is typically supplied as a lyophilized powder. Specific pharmacokinetic parameters such as half-life, bioavailability, and plasma protein binding are not applicable as SCPB is a research tool used primarily in invertebrate models.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SCPB is not extensively documented as it is a naturally occurring neuropeptide used in research settings. At physiological concentrations, SCPB modulates cardiac and neuromuscular functions without cytotoxic effects. Specific LD50 values and organ-specific toxicity data are not available for this research peptide.
|
| References | |
| Additional Infomation |
SCPB (CAS# 84746-43-0) is also known as Small Cardioactive Peptide B. It is a neurally active peptide that stimulates adenylate cyclase activity in heart and gill tissues. The peptide is a valuable tool for researchers investigating the molecular mechanisms underlying peptide-mediated regulation of physiological processes, particularly in invertebrate neurobiology and cardioregulation.
|
| Molecular Formula |
C52H80N14O11S2
|
|---|---|
| Molecular Weight |
1141.41
|
| Exact Mass |
1140.56
|
| CAS # |
84746-43-0
|
| PubChem CID |
123843
|
| Appearance |
White to off-white solid powder
|
| Density |
1.41 g/cm3
|
| Index of Refraction |
1.656
|
| LogP |
4.051
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
34
|
| Heavy Atom Count |
79
|
| Complexity |
2070
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCSC)N
|
| InChi Key |
IDATZUYVZKJKRE-SXMXEBDWSA-N
|
| InChi Code |
InChI=1S/C52H80N14O11S2/c1-29(2)25-37(63-48(74)38(26-32-15-17-33(67)18-16-32)64-49(75)39(28-42(54)68)62-45(71)34(53)19-23-78-4)47(73)59-30(3)44(70)65-40(27-31-11-7-6-8-12-31)51(77)66-22-10-14-41(66)50(76)61-36(13-9-21-58-52(56)57)46(72)60-35(43(55)69)20-24-79-5/h6-8,11-12,15-18,29-30,34-41,67H,9-10,13-14,19-28,53H2,1-5H3,(H2,54,68)(H2,55,69)(H,59,73)(H,60,72)(H,61,76)(H,62,71)(H,63,74)(H,64,75)(H,65,70)(H4,56,57,58)/t30-,34-,35-,36-,37-,38-,39-,40-,41-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]butanediamide
|
| Synonyms |
Met-asn-tyr-leu-ala-phe-pro-arg-met-NH2; SCPB; Small cardioactive peptide B
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~43.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8761 mL | 4.3805 mL | 8.7611 mL | |
| 5 mM | 0.1752 mL | 0.8761 mL | 1.7522 mL | |
| 10 mM | 0.0876 mL | 0.4381 mL | 0.8761 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
